Vantage Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vantage Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$57K	Hold	655	–	–	0.01%	263
2018 Q2	$65K	Hold	655	–	–	0.02%	238
2018 Q1	$78K	Buy	655 +400	+157%	+$51.6K	0.02%	231
2017 Q4	$32K	Buy	255 +100	+65%	+$12.6K	0.01%	369
2017 Q3	$18K	Buy	155 +128	+474%	+$10.9K	﹤0.01%	453
2017 Q2	$2K	Hold	27	–	–	﹤0.01%	700
2017 Q1	$1K	Hold	27	–	–	﹤0.01%	727
2016 Q4	$1K	Hold	27	–	–	﹤0.01%	742
2016 Q3	$2K	Hold	27	–	–	﹤0.01%	677
2016 Q2	$1K	Hold	27	–	–	﹤0.01%	757
2016 Q1	$2K	Hold	27	–	–	﹤0.01%	703
2015 Q4	$3K	Hold	27	–	–	﹤0.01%	659
2015 Q3	$2K	Buy	+27	New	+$3K	﹤0.01%	697

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vantage Investment Advisors's ALNY Position: Q3 2018 in Review

Vantage Investment Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2018 at 655 shares worth $57K. The position accounts for 0.01% of the portfolio, ranked #263.

Vantage Investment Advisors first reported a position in ALNY in Q3 2015 and has held it in 13 quarters since. The position peaked at $78K in Q1 2018. 305 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

Vantage Investment Advisors held 655 shares of Alnylam Pharmaceuticals worth $57K as of Q3 2018.
Vantage Investment Advisors left its Alnylam Pharmaceuticals share count unchanged in Q3 2018.
Alnylam Pharmaceuticals made up 0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #263 holding.
Vantage Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 13 quarters since.
Vantage Investment Advisors's Alnylam Pharmaceuticals position peaked at $78K in Q1 2018.
305 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.